Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
23 Cards in this Set
- Front
- Back
|
rate limiting step in hepatic cholesterol synthesis
|
HMG-CoA reductase makes mevalonic acid from HMG-CoA
|
|
|
drugs associated with reduced LDL cholesterol levels and anti-atherosclerotic effects
|
statins
|
|
|
adverse effects of statins
|
myopathy
hepatic dysfunction teratogen |
|
|
drugs that reduce risk of coronary events and mortality in patients with ischemic heart disease
|
statins
|
|
|
what is different about simvastatin, atorvastatin, and rosauvastatin
|
greater maximal efficacy and reduce triglycerides as well as increase HDL cholesterol
|
|
|
three drugs that prevent reabsorption of bile acids
|
resins -
colesvelam cholestyramine colestipol |
|
|
adverse affects of resins
|
bloating, constipation, impaired reabsorption of vitamins and some drugs
|
|
|
used in patients with hypercholesterolemia and can reduce pruritis in patients with cholestasis
|
resins
colesvelam cholestyramine colestipol |
|
|
what disease can precipitate increase triglycerides and VLDL while taking resins
|
familial combined hyperlipidemia
|
|
|
inhibits sterol transporter in GI tract
|
Ezetimibe
|
|
|
prevents reabsorption of dietary cholesterol and cholesterol excreted by bile
|
ezetimibe
|
|
|
when is ezetimibe used
|
elevated LDL cholesterol or phytosterolemia
|
|
|
reduces LDL cholesterol by 18% in monotherapy
|
ezetimibe
|
|
|
PPAR-a agonists
|
fenofibrate
gemfibozil |
|
|
results in increased synthesis of lipoprotein lipoase in adipocytes
|
PPAR-a agonists (fibrates)
fenofibrate gemifibozil |
|
|
when are PPAR-a agonists used
|
hypertriglyceridemia or low HDL cholesterol
|
|
|
adverse effects of PPAR-a agonists
|
nausea, decreased WBC or hematocrit rare, be careful in patients with previous cholelithiasis
|
|
|
be care in patients with previous cholelithiasis
|
PPAR-a agonists (fibrates)
|
|
|
when can fibrates increase LDL cholesterol
|
familial combined hyperlipoproteinemia
|
|
|
reduces VLDL syntehsis, LDL, triglycerides, and increases HDL levels
|
niacin
|
|
|
drug increases fibrinolysis by decreases circulating fibrinogen and increasing tissue plasminogen activator
|
niacin
|
|
|
adverse effects of niacin
|
flushing, hepatic toxicity, hyperuricemia
|
|
|
treatment of hypercholesterolemia, hypertriglyceridemia, and low levels of cholesterol
|
niacin
|
